SereNeuro Therapeutics

Living pain neurons that absorb joint pain.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Baltimore, MD, USA
  • Currency USD
  • Founded March 2024
  • Employees 4
  • Incorporation Type C-corp
  • Website linkedin.com

Company Summary

Pipeline:

• SN101 (Osteoarthritis): Our lead asset. It is the only therapy that stops pain, preserves cartilage and remodels health bone/nerve tissue. Non-human primates study in process. https://www.eurekalert.org/news-releases/1108417

• SN102 (Neuropathic Pain): Treats Trigeminal Neuralgia (the "suicide disease"). Current standard of care requires invasive brain surgery; we offer a non-invasive cure.

Team

  • Daniel Saragnese
    CEO & Co - Founder

    Led CMC, Finance, and Operations at venture-backed biotech spin-outs of Stanford and Johns Hopkins

  • Tea Soon Park PhD
    Sr. Principal Scientist - Cell Therapy

    As a stem cell scientist, Tea Soon has over 15 years of expertise in regenerative medicine and pluripotent stem cell biology.

  • Aakarsh Malhotra
    External Business Development

    Startup advisor, venture and ecosystem builder, previously accelerator programs and operations lead. 7+ years experience in startups, investments, M&A consulting and entrepreneurship.

  • Thomas Haag
    General Counsel, Strategic Advisor

    Ph.D. Molecular Biologist, venture capitalist, and veteran IP attorney delivers high-value IP portfolios and landmark transactions for life science companies at all stages.

    Thomas co-founded and lead AexeRNA Therapeutics, which was acquired in late 2023 by BioNTech SE (NASDAQ: BNTX)

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free